CA1302891C - Pharmaceutical formulations of acid labile substances for oral use - Google Patents

Pharmaceutical formulations of acid labile substances for oral use

Info

Publication number
CA1302891C
CA1302891C CA000535903A CA535903A CA1302891C CA 1302891 C CA1302891 C CA 1302891C CA 000535903 A CA000535903 A CA 000535903A CA 535903 A CA535903 A CA 535903A CA 1302891 C CA1302891 C CA 1302891C
Authority
CA
Canada
Prior art keywords
alkaline
acid
compound
preparation according
labile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000535903A
Other languages
French (fr)
Inventor
Kurt Ingmar Lovgren
Ake Gunnar Pilbrant
Mitsuru Yasumura
Satoshi Morigaki
Minoru Oda
Naohiro Ohishi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hassle AB
Original Assignee
Hassle AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10597119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA1302891(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hassle AB filed Critical Hassle AB
Application granted granted Critical
Publication of CA1302891C publication Critical patent/CA1302891C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Abstract

ABSTRACT

Pharmaceutical preparation containing an acid labile compound together with an alkaline reacting compound or an alkaline salt of an acid labile compound optionally together with an alkaline compound as the core material, one or more subcoating layers comprising inert reacting compounds which are soluble or rapidly disintegrating in water, or polymeric, water soluble filmforming compounds, optionally containing pH-buffering alkaline compounds and an enteric coating as well as a process for the preparation thereof and the use in the treatment of gastrointestinal diseases.

Description

13~2~1 Field of the Invention The present invention is related to new pharmaceutical preparations containing acid labile substances for oral use, to a method for the manufacture of such preparations and to a method of affecting gastrlc acid secretion and providing gastrointestinal cytoprotective effect when using them.
Backaround of the Invention Acid labile substances present a problem to the formulator when formulating a pharmaceutical dosage form for oral use. In order to prevent the substances from contact with the acid reacting gastric juice after oral intake, the conventional way to solve this problem is to coat the dosage form with an enteric coating. The coating is a group of substances/polymers with the common feature of being practically insolubls in acid media, while they are soluble in neutral to alkaline media. For substances that are labile in acid media, but have better stability in neutral to alkaline media, it is often advantageous to add alkaline reacting inactive constitu@nts in order to increase the stability of the active compound during manufacture and storage.
The present invention provides a pharmaceutical preparation comprising (a) an alkaline reacting core region comprising an acid-labile pharmaceutically active substance and an alkaline reacting compound different from said active substance, an alkaline salt of an acid-labile pharmaceutically active substance, or an alkaline salt of an acid-labile pharmaceutically active substance and an 'r~.' ~3~2~

alkaline reacting compound differen~ from said active substance;
(b) an inert subcoating, which will rapidly dissolve or disintegra~e in water, said subcoating being disposed on said core region and comprising one or more layers of materials selected from the group consisting of tablet excipients, film-forming compounds and alkaline compounds; and (c) an enteric coating layer surrounding said subcoating layer, wherein the subcoating layer isolates the alkaline reacting core from the enteric coating layer such that the stability of the preparation is enhanced.
A group of compounds exerting these stability properties are substituted benzimidazoles with the general formula I

Rl A CH-S ~ / ; R2 NH i R3 wherein A is an optionally substituted heterocyclic group and R1, R2, R3 and R4 are the same or different and are hydrogen, lower alkyl, lower alkoxy, -CF3, -O-C-lower alkyl or halogen, and R5 is H or a lower alkyl, or the compound 2-[(2-dimethylaminobenzyl)-sulfinyl]-benzimidazole.

la i 13~21~

The compounds with the general formula I are virtually biologically inactive as such, but degrade/transform to active inhibitors of certain enzyme systems in acid media.

As examples of compounds with the mentioned properties the compounds described in the patents US-A-4045 563, EP-Bl-O 005 129 and BE-898 880 and the patent applications EP-85850258,6, EP-Al-O 080 602, EP-0127 736, EP-O 134 400, EP-O 130 729, EP-O 150 586, DE-3415971 GB-2 082 580 and SE-A-8504048-3 may be mentioned. The last application describes 2- (2-disubstituted-aminobenzyl)sulfinyl benzimidazoles, e.g. 2- (2-di--methylaminobenzyl)sulfinyl benzimidazole, also called, NC-1300 and presented by Prof. S. Okabe at the Symposium on Drug Activity held on Oct 17th 1985 in Nagoya, Japan, and which interacts with the H+K+-ATPase after acid degradation within the parietal cells. (See for instance B.
Wallmark, A. Brandstrom and H. Larsson "Evidence for acid-induced transformation of omeprazole into an active inhibitor of H+K+-ATPase within the parietal cell", Biochemica et Biophysica Acta 778, 549-558, 1984). Other compounds with similar properties are further mentioned in the patent US-4 182 766 and the patent applications GB-2 141 429, EP-O
146 370 and GB-2 082 580. A common feature of these compounds are that they are transformed into the biologically active compounds via rapid degradation/transformation in acid media.

The stability profile of some compounds with the general formula I above is exemplified in the Table 1 below, where the half-life of the degradation/transformation reaction in solution at pH 2 and 7 are given.

~ Z~

Table 1. Rate of deqradation/transformation of compounds __ _ __ _ _ with the general structure S A --CH2 - - // ~ 23 Compound Half-life (minutes) for the No transformation to the active moiety A R2 R3 at pH = 2 at pH = 7 1. ~ 5-COOCH3;6-CH3 11 150 "~ , 3 l 5-CH3;H 5.4 1700 N
3. ~ 5-CF3;H 1.9 122 ~3 5-CF3;H 2.0 8.8 N

C2H5 ~>
5. ~ 5-OCH3;H 3.7 1620 N

Cont.

3~8~

Compound Half-life (minutes) for the No transformation to the active moiety A R2 R3 at pH = 2 at pH = 7 0~

6. ~ 5-OCH3;H 4.0 3900 7 ~ ~ - 5-C2H5;H 33 not determined ¢3~

Substituted sulfoxides, such as for instance the substituted benzimidazoles described in EP-Bl-0005129 are potent inhibitors of gastric acid secretion. The substituted benzimidazoles are susceptible to degradation/transformation in acid reacting and neutral media.

It is an inherent property of these compounds to be activated to the active moiety in the acid environment within the parietal cells. The activated compound interacts with the enzyme in the parietal cells, which mediates the production of hydrochloric acid in the gastric mucosa. All compounds of the class of substituted benzimidazoles, containing a sulfoxide grouping, which interferes with the H K+--ATPase in the parietal cells hitherto known are all also degraded in acid media.

A pharmaceutical dosage form of acid labile substances, which prevents the substances from contact with acidic gastric juice, must be enteric coated. Ordinary enteric coatings, however, are made of acidic compounds. If covered with such a conventional enteric coating, the acid labile substance rapidily decomposes by direct or indirect contact with it, with the result that the preparations become badly discoloured and lose in content of the active compound with the passage of time.

In order to enhance the storage stability, the cores which contain the acid labi!e substance must also contain alkaline reacting constituents.
When such an alkaline core is enteric coated with an amount of a conventional enteric coating polymer such as, for example, cellulose acetate phthalate, that permits the dissolution of the coating and the active drug contained in the cores in the proximal part of the small intestine, it also will allow some diffusion of water or gastric juice through the enteric coating into the cores, during the time the dosage form resides in the stomach before it is emptied into the small intestine. The diffused water or gastric juice will dissolve parts of the core in the close proximity of the enteric coating layer and there form an alkaline solution inside the coated dosage form. The alkaline solution will interfere with the enteric coating and eventually dissolve it.

13~

In D~-Al-3 046 559 a way to coat a dosage form is described. First the dosage form is coated with a water insoluble layer containing microcrystalline cellulose and then with a second enteric coating with the aim to achieve a dosage form which releases the active drug in the 5 colon. This method of preparation will not give the desired release of the compounds with the general formula I above in the small intestine.

US-A-2 540 979 describes an enteric coated oral dosage form, where the enteric coating is combined with a second and/or first coating of a 10 water insoluble "wax" layer. This method of preparation is not applicable on cores containing a compound with the general formula I
since direct contact between substances such as cellulose acetate phthalate (CAP) and a compound of formula I causes degradation and discolouration of the compounds of the formula I.
DE-B2-23 36 218 describes a method to produce a dialysis membrane consisting of a mixture of one or more conventional enteric coating polymers and one or more insoluble cellulose derivatives. Such a membrane will not give a proper protection of the acid labile compounds 20 of the formula I in gastric juice.

DE-Al-l 204 363 describes a three-layer coating procedure. The first layer is soluble in gastric but is insoluble in intestinal juice. The second is water soluble regardless of pH and the third layer is an 25 enteric coating. This preparation as well as the preparation described in DE-Al-l 617 615 result in a dosage form which is not dissolved in gastric juice and which only dissolves slowly in intestinal juice. Such preparations cannot be used for the compounds of the formula I, where a rapid release of the drug in the small intestine is needed. DE-Al 12 04 30 363 describes coating with three layers to achieve release of a drug in the ileum, an aim which is outside the scope of the present invention.
GB-A-l 485 676 describes a way to obtain a preparation which effervesces in the small intestine. This is obtained by the enteric coating of a core containing the active drug and an effervescing system such as a ~13~Z8~

combination of carbonate and/or bicarbonate salt and a pharmaceutically acceptable acid. This formulation cannot be adopted for a pharmaceutical dosage form containing a compound of formula I as the presence of an acid in contact with a compound of formula I in the cores would give as a result that the compound of formula I was degraded.

W0 85/03436 describes a pharmaceutical preparation, wherein cores containing active drugs mixed with for instance buffering components such as sodium dihydrogenphosphate with the aim of maintaining a constant pH and a constant rate of diffusion, are coated with a first coating which controls the diffusion. This formulation cannot be adopted for acid labile compounds where a rapid release in the small intestive is wanted. Direct application of an enteric coating onto the cores would also adversely influence the storage stability of such dosage forms containing acid labile compounds.

Outline of the invention According to the present invention it has been found that the known acid labile compounds with the general formula I above in which Rl, R2, R3 and R4 are the same or different and are 13~Z8~1 (a) hydrogen (b) halogen, e.g. F, Cl, Br, I
(c) -CN
(d) -CH0 - (e) -CF3 (f) -C-Rll (g) -O-e-R12 (h) -CH(oR13)2 ( i ) - ( Z ) n-B-D
(j) aryl containing up to 10 carbon atoms (k) aryloxy containing up to 10 carbon atoms, optionally substituted by alkyl containing 1-6 carbon atoms ~1) -alkylthio containing 1-6 carbon atoms (m) -N0 (n) -alkylsulfinyl containing 1-6 carbon atoms (o) or wherein adjacent groups Rl R2 R3 and R4 together with the adjacent carbon atoms in the benzimidazole ring form a S-, 6- or 7-membered monocyclic ring or a 9-, 10- or ll-membered bicyclic ring, which rings may be saturated or unsaturated and may contain 0-3 hetero atoms selected from -N- and -0-, and which rings may be optionally substituted with 1-4 substituents selected from alkyl groups with 1-3 carbon atoms, alkylene radicals containing 4-5 carbon atoms giving spiro compounds, or two or four of these substituents together form one or two oxo groups o (-C-), whereby if Rl and R2, R2 and R3 or R3 and , ., `` ~3~2~

R4 together with the adjacent carbon atoms in the benzimidazole ring form two rings they may be condensed with each other, in which formulas Rll and R12, which are the same or different, are (a) aryl containing up to 10 carbon atoms (b) alkoxy containing 1-4 carbon atoms (c) alkoxyalkoxy containing 1-3 carbon atoms in each alkoxy part (d~ arylalkoxy containing 1-2 carbon atoms in the alkoxy part and up to 10 carbon atoms in the aryl part (e) aryloxy containing up to 10 carbon atoms (f) dialkylamino containing 1-3 carbon atoms in the alkyl parts, or (g) pyrrolidino or piperidino, optionally substituted with alkyl containing 1-3 carbon atomsi R13 is (a) alkyl containing 1-4 carbon atoms, or (b) alkylene containing 2-3 carbon atoms;

25 Z is -0- or -C- ;

n is 0 or 1;

B is (a) alkylene containing 1-6 carbon atoms (b) cycloalkylene containing 3-6 carbon atoms ~o (c) alkenylene containing 2-6 carbon atoms (d) cycloalkylene containing 3-6 carbon atoms, or (e) alkynylene containing 2-6 carbon atoms;

D is (a) H
(b) -CN
o (c) -C-R9 ~d) ~(Y)m ~(C)r ~Rl wherein lS R is (a) alkoxy containing l-S carbon atoms, or (b) dialkylamino containing 1-3 carbon atoms in the alkyl parts;

m is 0 or 1;

r is 0 or 1;
.

Y is (a) -0-(b) -NH-(c) -NR10_;

R10 is (a) H
(b) alkyl containing 1-3 carbon atoms (c) arylalkyl containing 1-2 carbon atoms in the alkyl part and up to 10 carbon atoms in the aryl part 13UZ8~

(d) aryl containing up to 10 carbon atoms;
RS is H, CH3 or C2H5; R7 A is especially a pyridyl group R ~ 8 in which R6 and R8 are the same or different, are ~ N

ta) H or (b) alkyl containing 1-6 carbon atoms;

R is (a) H
(b) alkyl containing 1-8 carbon atoms (c) alkoxy containing 1-8 carbon atoms (d) alkenyloxy containing 2-5 carbon atoms (e) alkynyloxy containing 2-5 carbon atoms (f) alkoxyalkoxy containing 1-2 carbon atoms in each alkoxy group (g) aryl containing up to 10 carbon atoms (h) arylalkyl containing 1-6 carbon atoms in the alkyl part and up to 10 carbon atoms in the aryl : part (i) aryloxy containing up to 10 carbon atoms, optionally substituted by alkyl containing 1-6 carbon atoms (j) arylalkoxy containing 1-6 carbon atoms in the alkoxy part and up to 10 carbon atoms in the aryl part (k) dialkylaminoalkoxy containing 1-2 carbon atoms in the alkyl substituents on the amino nitrogen and 1-4 carbon atoms in the alkoxy group (1) oxacycloalkyl containing one oxygen atom and 3-7 carbon atoms (m) oxacycloalkoxy containing two oxygen atoms and 4-7 carbon atoms (n) oxacycloalkylalkyl containing one oxygen atom and 4-7 carbon atoms ~3~

(o) ov~acycloalkylalkoxy containing two oxygen atoms and 4-6 carbon atoms, or (p) R6 and R7, or R7 and R8 together with the adjacent carbon atoms in the pyridine ring form S a ring wherein the part constituted by R6 and R7, or R7 and R8, is -CH=CH-CH=CH--O- ( CH2 ) p--S- ( CH2 ) V--CH2 ( CH2 ) p--O-CH=CH--NH-CH=CH--~-CH=CH-wherein p is 2, 3 or 4, v is 2 or 3 and the O and N atoms always are attached to position 4 in the pyridine ring; provided that not more than one of R6, R7 and R8 is hydrogen can be formulated into an enteric coated dosage form.
The object of the present invention is thus an enteric coated dosage form of acid labile compounds with the general formula I defined above except the compound omeprazole, 5-methoxy-2- (4-methoxy-3,5 dimethyl--2-pyridinyl methyl sulfinyl lH benzimidazole. Another compound, which may be enteric coated according to the invention is 2- (2-dimethyl-aminobenzyl)sulfinyl -benzimidazole. The new preparations are resistant to dissolution in acid media, dissolve rapidly in neutral to alkaline media and have a good stability during long-term storage. The new dosage form is characterized in the following way. Cores containing the acid labile compound mixed with alkaline compounds or an alkaline salt of the acid labile compound optionally mixed with an alkaline compound are coated with two or more layers, whereby the first layer/layers is/are soluble in water or rapidly disintegrating in water and consist(s) of non-acidic, otherwise inert pharmaceutically acceptable substances.
This/these first layer/layers separates/separate the alkaline core material from the outer layer, which is an enteric coating. The final, enteric coated dosage form is treated in a suitable way to reduce the water content to a very low level in order to obtain a good 13~

stability of the dosage form during long-term storage.

As examples of compounds especially suitable for the pharmaceutical dosage form according to the invention the compounds listed in Table 1 can be mentioned.

The half-life of degradation of the compounds 1-6 in Table 1 in water solution at pH-values less than four is in most cases shorter than ten minutes. Also at neutral pH-values the degradation reaction proceeds rapidly, e.g. at pH=7 the half-life of degradation is between 10 minutes and 65 hours while at higher pH-values the stability in solution for most compounds is much better. The stability profile is similar in solid phase. The degradation is catalyzed by acid reacting substances. The acid labile compounds are stabilized in mixtures with alkaline reacting substances.

From what is said about the stability properties of the acid labile compounds listed above it is obvious that an oral dosage form of the said compounds must be protected from contact with the acid reacting gastric juice in order to reach the small intestine without degradation.

Detailed description of the invention Cores The acid labile active compound is mixed with inert, preferably water soluble, conventional pharmaceutical constituents to obtain the preferred concentration of the active compound in the final mixture and with an alkaline reacting, otherwise inert, pharmaceutically acceptable substance (or substances), which creates a "micro-pH" around each particle of active compound of not less than pH=7, preferably not less than pH=8, when water is adsorbed to the particles of the mixture or when water is added in small amounts to the mixture. Such substances can be chosen among, but are not restricted to substances such as the sodium, potassium, calcium, magnesium and aluminium salts of phosphoric acid, carbonic acid, citric acid or other suitable weak inorganic or organic acids; substances normally used in antacid preparations such as ~3~

aluminium, calcium and magnesium hydroxides; magnesium oxide or composite substances such as A1203.6MgO C02.12H20, (Mg6A12(0H)16C03 4H20), MgO.A1203.2SiO2.nH20, wherein n not is an integer and less than 2 or similar compounds; organic pH-buffering substances such as trishydroxymethylaminomethane or other similar, pharmaceutically acceptable pH-buffering substances. The stabilizing, high pH-value in the powder mixture can also be achieved by using an alkaline reacting, salt of the active compound such as the sodium, potassium, magnesium, calcium etc. salts of acid labile compounds,either alone or in combination with a conventional buffering substance as previously described.

The powder mixture is then formulated into small beads i.e. pellets or tablets, by conventional pharmaceutical procedures. The pellets, tablets or gelatin capsules are used as cores for further processing.
Separating layer The alkaline reacting cores containing an acid labile compound must be separated from the enteric coating polymerts) containing free carboxyl groups, which otherwise causes degradation/discolouration of the acid labile compound during the coating process or during storage. The subcoating layer, (the separating layer), also serves as a pH-buffering zone in which hydrogen ions diffusing from the outside in towards the alkaline core can react with hydroxyl ions diffusing from the alkaline core towards the surface of the coated articles. The pH-buffering properties of the separating layer can be further strengthened by introducing in the layer substances chosen from a group of compounds usually used in antacid formulations such as, for instance, magnesium oxide, hydroxide or carbonate, aluminium or calcium hydroxide, carbonate or silicate; composite aluminium/magnesium compounds such as, for instance A1203.6MgO C2-12H2o~ (M96A 2( 16 3 2 MgO.A1203.2SiO2.nH20, wherein n not is an integer and less than 2 or similar compounds; or other pharmaceutically acceptable pH-buffering substances such as, for instance the sodium, potassium, calcium, magnesium and aluminium salts of phosphoric, citric or other suitable, weak, inorganic or organic acids.

13~}2~3~33L

The separating layer consists of one or more water soluble inert layers, optionally containing pH-buffering substances.

The separating layer(s) can be applied to the cores - pellets or tablets - by conventional coating procedures in a suitable coating pan or in a fluidized bed apparatus using water and/or conventional organic solvents for the coating solution. The material for the separating layer is chosen among the pharmaceutically acceptable, water soluble, inert compounds or polymers used for film-coating applications such as, for instance sugar, polyethylene glycol, polyvinylpyrollidone, polyvinyl alcohol, hydroxypropyl cellulose, hydroxymethyl cellulose, hydroxypropyl methylcellulose or the like. The thickness of the separating layer is not less than 2 um, for small spherical pellets preferably not less than 4 um, for tablets preferably not less than 10 um.
In the case of tablets another method to apply the coating can be performed by the drycoating technique. First a tablet containing the acid labile compound is compressed as described above. Around this tablet another layer is compressed using a suitable tableting machine.
The outer, separating layer, consists of pharmaceutically acceptable, in water soluble or in water rapidly disintegrating tablet excipients. The separating layer has a thickness of not less than 1 mm. Ordinary plasticizers, pigments, titanium dioxide talc and other additives may also be included into the separating layer.
In the case of gelatin capsules the gelatin capsule itself serves as separating layer.

Enteric coating layer 3~
The enteric coating layer is applied on to the sub-coated cores by conventional coating techniques such as, for instance, pan coating or fluidized bed coating using solutions of polymers in water and/or suitable organic solvents or by using latex suspensions of said polymers. As enteric coating polymers can be used, for example, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phthalate, co-polymerized methacrylic acid/methacrylic acid methyl esters such as, for instance, compounds known under the ~3~Z~

trade name EudragitR L 12,5 or EudragitR L lOO,(Rohm Pharma) or similar compounds used to obtain enteric coatings.

The enteric coating can also be applied using water-based polymer ,~ 5 dispersions, e.g. Aquateric (FMC Corporation), EudragitR L 100-55 (Rohm ``` Pharma), Coating CE 5142 (BASF). The enteric coating layer can optionally contain a pharmaceutically acceptable plasticizer such as, for instance, cetanol, triacetin, citric acid esters such as, for instance, those known under the trade name CitroflexR (Pfizer) phthalic acid esters, dibutyl succinate or similar plasticizers.

The amount of plasticizer is usually optimized for each enteric coating polymer(s) and is usually in the range of 1-20 % of the enteric coating polymer(s). Dispersants such as talc, colourants and pigments may also be included into the enteric coating layer.

Thus the special preparation according to the invention consists of cores containing the acid labile compound mixed with an alkaline reacting compound or cores containing an alkaline salt of the acid labile compound optionally mixed with an alkaline reacting compound. The cores suspended in water forms a solution or a suspension which has a pH, which is higher than that of a solution in which the polymer used for enteric coating is just soluble. The cores are coated with a water soluble or in water rapidly disintegrating coating, optionally containing a pH-buffering substance, which separates the alkaline cores from the enteric coating. Without this separating layer the resistance towards gastric juice would be too short and the storage stability of the dosage form would be unacceptably short. The sub-coated dosage form is finally coated with an enteric coating rendering the dosage form insoluble in acid media, but rapidly disintegrating/dissolving in neutral to alkaline media such as, for instance the liquids present in the proximal part of the small intestine, the site where dissolution is wanted.

Final dosage form The final dosage form is either an enteric coated tablet or capsule or in the case of enteric coated pellets, pellets dispensed in hard gelatin 7 rade mAr K

13~8~

capsules or sachets or pellets formulated into tablets. It is essential for the long term stability during storage that the water content of the final dosage form containing acid labile compound (enteric coated tablets, capsules or pellets) is kept low, preferably not exceeding 1.5 % by weight.

Process A process for the manufacture of the oral dosage form represents a further aspect of the invention. After the forming of the cores the cores are first coated with the separating layer and then with the enteric coating layer. The coating is carried out as described above.

The preparation according to the invention is especially advantageous in reducing gastric acid secretion and/or providing a gastrointestinal cytoprotective effect. It is usually administered one to several times a day. The typical daily dose of the active substance varies and will depend on various factors such as for example the individual requirement of the patients, the mode of administration and the disease. In general the dosage will be in the range of 1 to 400 mg per day of active substance. A method for the treatment of such conditions using the vovel oral dosage form represents a further aspect of the invention.

The invention is described in detail in the following examples:
EXAMPLES

Examples 1 - 3 exemplify the invention.

Example 1 Uncoated pellets ~Lactose powder 253 g ~ Lactose anhydrous 167 9 I ~Hydroxypropyl cellulose 25 9 13~

j Compound 1, Table I 50 9 Sodium lauryl sulphate 5 9 II Disodium hydrogen phosphatel.S g I Sodium dihydrogen phosphate0.1 9 ~Distilled water 125 9 The dry ingredients ~I) were premixed in a mixer. Addition of a granulation liquid (II) containing ~he suspended active compound was made and the mass was wet-mixed to a proper consistency. The wet mass was pressed through an extruder and spheronized to pellets. The pellets were dried and classified into suitable particle size ranges.

Subcoated pellets Uncoated pellets 500 9 rHydroxypropyl methyl-III ~ cellulose 20 9 ~Distilled water 400 9 The polymer solution (III) was sprayed onto the uncoated pellets in a fluidized bed apparatus. The spray guns were placed above the fluidized bed.

Enteric coated pellets Subcoated pellets 500 9 rHydroxypropyl methylcellulose ~ phthalate 57 9 IV ~ Cetyl alcohol 3 9 1 Acetone 540 9 ~Ethanol 231 9 The polymer solution (IV) was sprayed on the subcoated pellets in a fluidized bed apparatus with spray guns placed above the bed. After drying to a water content of 0.5 % the enteric coated pellets were classified and filled into hard gelatin capsules in an amount of 284 mg, corresponding to 25 mg of active compound 1. 30 capsules were packed in tight containers together with a desiccant.

`` ~3~2~

Example 2 Formulation with the sodium salt of compound 2 according to Table I.

Uncoated pellets rCompound 2, Table I sodium salt 339 9 ) Mannitol powder 2 422 9 Lactose anhydrous 120 9 I Hydroxypropyl cellulose 90 9 ~icrocrystalline cellulose60 9 II ~ Sodium lauryl sulphate 7 9 ~Distilled water 650 9 The preparation was made as described in Example 1 with the exception that the sodium salt of compound 2 was added together with the other ingredients in mixture I.

20 Subcoated pellets Uncoated pellets 500 9 rHydroxypropyl methylcellulose 20 g III ~ Aluminium hydroxide/magnesium I carbonate 4 9 ~,Distilled water 400 9 Pellets subcoated with III 500 9 IV ~Hydroxypropyl methylcellulose 20 9 ' Distilled water 400 9 The two subcoat layers, III and IV, were applied to the uncoated pellets in a fluidized bed apparatus in consecutive order as previously described.

~3~

Enteric coated pellets Subcoated pellets 500 9 ~ Hydroxypropyl methylcellulose ¦ phthalate 57 9 V~ Cetyl alcohol 3 9 Acetone 540 9 ~Ethanol 231 9 The preparation of enteric coated pellets was performed as described in Example 1.

Example 3 Formulation with compound 6, according to Table 1. This example gives the composition of one unit dose according to the invention.

Tablet core 20 Compound 6, Table 1 15 mg Lactose 119 mg Hydroxypropyl cellulose (low substitution) 5 mg Hydroxypropyl cellulose 1 mg 25 Talc 5 mg Mg(OH)2 15 mg Total 160 mg Tablet cores having the composition above and each weighing 160 mg were first made by known techniques.

Separating layer (inner) Hydroxypropyl cellulose 2 mg 35 Synthetic hydrotalcite 0.3 mg LA1203.6M90.CO2.12H20~

` ~3 S rating layer (outer) Hydroxypropyl cellulose 2 mg S The two separating layers were applied to the cores by known coating techniques.

Enteric coating layer 10 Hydroxypropyl methylcellulose phthalate 7 mg Cetyl alcohol 0.5 mg The enteric coating solution was sprayed on the cores coated by the two separating layers by known enteric coating techniques.

Claims (19)

1. A pharmaceutical preparation comprising (a) an alkaline reacting core region comprising an acid-labile pharmaceutically active substance and an alkaline reacting compound different from said active substance, an alkaline salt of an acid-labile pharmaceutically active substance, or an alkaline salt of an acid-labile pharmaceutically active substance and an alkaline reacting compound different from said active substance;
(b) an inert subcoating, which will rapidly dissolve or disintegrate in water, said subcoating being disposed on said core region and comprising one or more layers of materials selected from the group consisting of tablet excipients, film-forming compounds and alkaline compounds; and (c) an enteric coating layer surrounding said subcoating layer, wherein the subcoating layer isolates the alkaline reacting core from the enteric coating layer such that the stability of the preparation is enhanced.
2. A preparation according to claim 1 wherein the acid-labile compound is a benzimidazole compound.
3. A preparation according to claim 1, wherein the acid-labile compound has the general formula I

wherein A is an optionally substituted heterocyclic group, R1, R2, R3 and R4 are the same or different and are hydrogen, lower alkyl, lower alkoxy, -CF3, -O-?-lower alkyl or halogen, and R5 is H or a lower alkyl group wherein "lower" denotes 1 to 6 carbon atoms, but is other than the compound omeprazole, 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole; or the acid-labile compound is 2-[(2-dimethylaminobenzyl)sulfinyl]-benzimidazole.
4. A preparation according to claim 3 wherein in the compound of formula I A is selected from the group consisting of 3-methylpyrid-2-yl, 3,5-dimethylpyrid-2-yl, 4-methoxypyrid-2-yl, 3-methyl-4-methoxypyrid-2-yl, 5-ethyl-4-phenoxypyrid-2-yl, 4-phenoxypyrid-2-yl and 1-methylbenzimidazol-2-yl, R1, R4 and R5 are each hydrogen, R2 is selected from the group consisting of methoxycarbonylmethyl, trifluoromethyl, methoxy and ethyl and R3 is selected from the group consisting of hydrogen and methyl.
5. A preparation according to claim 1, 2, 3 or 4 wherein the subcoating layer comprises one or more of magnesium oxide, magnesium hydroxide or composite substance Al2O3.6MgO.CO2.12H2O, (Mg6Al2(OH)16CO3.4H2O) or MgO.Al2O3.2SiO2.nH2O, wherein n is a number other than an integer and is less than two.
6. A preparation according to claim 1, 2, 3 or 4 wherein the sub-coating comprises two or more sub-layers.
7. A preparation according to claim 5 wherein the sub-coating comprises two or more sub-layers.
8. A preparation according to claim 5 wherein the sub-coating comprises hydroxypropyl methylcellulose, hydroxypropyl cellulose or polyvinylpyrrolidone.
9. A preparation according to claim 6 or 7 wherein the sub-coating comprises hydroxypropyl methylcellulose, hydroxypropyl cellulose or polyvinylpyrrolidone.
10. A preparation according to claim 1, 2, 3 or 4 wherein the alkaline core comprises the acid-labile compound and pH-buffering alkaline compound rendering to the micro-environment of the acid-labile compound a pH of 7 to 12.
11. A preparation according to claim 10 wherein the alkaline compound comprises one or more of magnesium oxide, hydroxide or carbonate, aluminium hydroxide, aluminium, calcium, sodium or potassium carbonate, phosphate or citrate, the composite aluminium/magnesium compounds Al2O3.6MgO.CO2.12H2O, (Mg6Al2(OH)16CO3.4H2O) or MgO.Al2O3.2SiO2.nH2O, wherein n is a number other than an integer and is less than two.
12. A preparation according to claim 1, 2, 3 or 4 wherein the alkaline core comprises an alkaline salt of the acid-labile compound.
13. A preparation according to claim 1, 2, 3 or 4 wherein the alkaline core comprises a sodium, potassium, magnesium, calcium or ammonium salt of the acid-labile compound.
14. A preparation according to claim 11 wherein the alkaline core comprises an alkaline salt of the acid-labile compound mixed with an inert, alkaline compound.
15. A preparation according to claim 1, 2, 3 or 4 wherein the enteric coating comprises hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, co-polymerized methacrylic acid/ methacrylic acid methyl ester or polyvinyl acetate phthalate.
16. A preparation according to claim 15 that also contains a plasticizer.
17. A preparation according to claim 1, 2, 3 or 4 wherein the water content of the final dosage form containing the acid-labile compound does not exceed 1.5% by weight.
18. A process for the production of an oral pharmaceutical preparation containing an acid-labile pharmaceutically active substance, which process comprises, coating a core region composed of the acid-labile pharmaceutically active substance together with an alkaline reacting compound different from the active substance or the acid-labile pharmaceutically active substance in the form of an alkaline salt, or the acid-labile pharmaceutically active substance in the form of an alkaline salt together with an alkaline reacting compound different from the active substance with one or more layers of material selected from the group consisting of tablet excipients, film-forming compounds and alkaline compounds to form an inert subcoating on said core region, which inert subcoating will rapidly dissolve or disintegrate in water; and coating the subcoating layer with an enteric layer, so that the subcoating layer isolates the alkaline reacting core region from the enteric coating layer such that the stability of the preparation is enhanced.
19. Use of the preparation according to claim 1 for the manufacture of a medicament for treatment of gastrointestinal diseases.
CA000535903A 1986-04-30 1987-04-29 Pharmaceutical formulations of acid labile substances for oral use Expired - Lifetime CA1302891C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8610573 1986-04-30
GB08610573A GB2189699A (en) 1986-04-30 1986-04-30 Coated acid-labile medicaments

Publications (1)

Publication Number Publication Date
CA1302891C true CA1302891C (en) 1992-06-09

Family

ID=10597119

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000535903A Expired - Lifetime CA1302891C (en) 1986-04-30 1987-04-29 Pharmaceutical formulations of acid labile substances for oral use

Country Status (33)

Country Link
US (1) US4853230A (en)
EP (3) EP0244380B1 (en)
JP (1) JPH0667837B2 (en)
KR (1) KR950004886B1 (en)
CN (1) CN1025151C (en)
AR (1) AR243377A1 (en)
AT (2) ATE139692T1 (en)
AU (1) AU603568B2 (en)
CA (1) CA1302891C (en)
CS (1) CS268535B2 (en)
CY (1) CY1860A (en)
DD (1) DD260222B5 (en)
DE (3) DE244380T1 (en)
DK (1) DK169987B1 (en)
DZ (1) DZ1078A1 (en)
EG (1) EG18517A (en)
ES (2) ES2010648T3 (en)
FI (1) FI91708C (en)
GB (1) GB2189699A (en)
GR (2) GR890300156T1 (en)
HK (2) HK104095A (en)
HU (1) HU198385B (en)
IE (1) IE61837B1 (en)
IS (1) IS1918B (en)
MY (1) MY102675A (en)
NO (1) NO174952C (en)
NZ (1) NZ220097A (en)
PH (1) PH24440A (en)
PL (1) PL265417A1 (en)
PT (1) PT84786B (en)
SU (1) SU1709894A3 (en)
YU (1) YU46421B (en)
ZA (1) ZA872379B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077541A (en) * 1997-11-14 2000-06-20 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation

Families Citing this family (226)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749864B2 (en) 1986-02-13 2004-06-15 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
US5433959A (en) * 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US5160743A (en) * 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US5006346A (en) * 1988-04-28 1991-04-09 Alza Corporation Delivery system
JPH0768125B2 (en) * 1988-05-18 1995-07-26 エーザイ株式会社 Oral formulation of acid labile compounds
JP2967492B2 (en) * 1989-05-11 1999-10-25 中外製薬株式会社 Intestinal in-place release oral formulation
GR1002098B (en) * 1989-06-08 1995-12-28 Squibb & Sons Inc Pharmaceutical composition having good stability
FI94339C (en) 1989-07-21 1995-08-25 Warner Lambert Co Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
KR930000861B1 (en) * 1990-02-27 1993-02-08 한미약품공업 주식회사 Omeprazole rectal composition
IT1245890B (en) * 1991-04-12 1994-10-25 Alfa Wassermann Spa PHARMACEUTICAL FORMULATIONS FOR ORAL USE GASTRORESANTS CONTAINING BILE ACIDS.
IT1245891B (en) * 1991-04-12 1994-10-25 Alfa Wassermann Spa CONTROLLED RELEASE PHARMACEUTICAL FORMULATIONS FOR ORAL USE GAS RESISTANT CONTAINING BILE ACIDS AND THEIR SALTS.
YU48263B (en) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. PROCEDURE FOR OBTAINING PANTOPRAZOLE PHARMACEUTICAL PRODUCT
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US7070806B2 (en) * 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
ZA937382B (en) * 1992-10-06 1994-04-29 Warner Lambert Co Novel composition for peroral therapy of cognitionimpairment and a process therefor
SE9301830D0 (en) * 1993-05-28 1993-05-28 Ab Astra NEW COMPOUNDS
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
TW280770B (en) 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
JPH07223970A (en) * 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd Releasing formulation at niche in digestive tract
SE9402431D0 (en) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SI1078628T1 (en) * 1994-07-08 2009-04-30 Astrazeneca Ab Multiple unit tableted dosage form
US5508276A (en) * 1994-07-18 1996-04-16 Eli Lilly And Company Duloxetine enteric pellets
SE9500422D0 (en) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (en) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
PL186605B1 (en) * 1995-09-21 2004-01-30 Pharma Pass Llc Novel pharmaceutic composition containing acid-labile omeprazole and method of preparing same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE512835C2 (en) * 1996-01-08 2000-05-22 Astrazeneca Ab Dosage form containing a plurality of units all containing acid labile H + K + ATPase inhibitors
SE9600070D0 (en) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9602442D0 (en) * 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5910319A (en) 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
SI9700186B (en) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Novel pharmaceutical preparation with controlled release of active healing substances
ES2137862B1 (en) * 1997-07-31 2000-09-16 Intexim S A ORAL PHARMACEUTICAL PREPARATION INCLUDING A COMPOUND OF ANTI-ULCER ACTIVITY AND PROCEDURE FOR ITS OBTAINING.
US6296876B1 (en) * 1997-10-06 2001-10-02 Isa Odidi Pharmaceutical formulations for acid labile substances
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
DE19752843C2 (en) * 1997-11-28 2003-01-09 Byk Gulden Lomberg Chem Fab Pharmaceutical preparation in tablet or pellet form for pantoprazole and omeprazole
AU1671799A (en) * 1997-11-28 1999-06-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Medicament preparation in the form of a tablet or pellet for acid-labile active substances
SE9704870D0 (en) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
DK173431B1 (en) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Pharmaceutical formulation comprising a 2 - [[(2-pyridinyl) methyl] sulfinyl] benzimidazole with anti-ulcer activity and progress
JP4127740B2 (en) * 1998-04-20 2008-07-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 Stabilized benzimidazole compound-containing composition
ATE348601T1 (en) 1998-05-18 2007-01-15 Takeda Pharmaceutical ORACULATE TABLET CONTAINING A BENZIMIDAZOLE
UA69413C2 (en) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Enteric coated pharmaceutical composition, pharmaceutical composition in form of spheroid beads, method for manufacturing pharmaceutical composition
US7122207B2 (en) 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
AUPP437698A0 (en) 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
UA73092C2 (en) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Tablets with enteric coating and method for their manufacture
DK1105105T3 (en) 1998-08-12 2006-07-17 Altana Pharma Ag Oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles
EP1121437B1 (en) 1998-10-15 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Metastatic breast and colon cancer regulated genes
WO2000026185A2 (en) * 1998-10-30 2000-05-11 The Curators Of The University Of Missouri Omeprazole solution and method of using same
TWI242000B (en) 1998-12-10 2005-10-21 Univ Southern California Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use
SI20109A (en) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stable pharmaceutical formulation
ES2310055T3 (en) 1998-12-16 2008-12-16 Novartis Vaccines & Diagnostic CYCLIN DEPENDENT HUMAN KINASE (HPNQALRE).
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation
US6197329B1 (en) 1999-05-03 2001-03-06 Drugtech Corporation Anti-nausea compositions and methods
CN1361683A (en) 1999-06-07 2002-07-31 比克·古尔顿·劳姆贝尔格化学公司 Novel preparation and administration form comprising an acid-labile active compound
IL130602A0 (en) * 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
ES2168043B1 (en) 1999-09-13 2003-04-01 Esteve Labor Dr PHARMACEUTICAL FORM ORAL SOLID MODIFIED RELEASE CONTAINING A COMPOSITE OF BENCIMIDAZOL LABIL IN THE MIDDLE ACID.
WO2001028559A1 (en) 1999-10-20 2001-04-26 Eisai Co., Ltd. Method for stabilizing benzimidazole compounds
DE19959419A1 (en) 1999-12-09 2001-06-21 Ratiopharm Gmbh Stable pharmaceutical preparations comprising a benzimidazole and process for their preparation
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
DE60134956D1 (en) 2000-01-10 2008-09-04 Novartis Vaccines & Diagnostic GENE DIFFERENTIALLY EXPERIMENTED IN BRUDTKREBS
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
US6306435B1 (en) 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
US6749867B2 (en) 2000-11-29 2004-06-15 Joseph R. Robinson Delivery system for omeprazole and its salts
WO2002045694A1 (en) 2000-12-07 2002-06-13 Altana Pharma Ag Rapidly disintegrating tablet comprising an acid-labile active ingredient
ES2403238T3 (en) 2000-12-07 2013-05-16 Takeda Gmbh Pharmaceutical preparation in the form of a suspension comprising an active ingredient labile in acidic medium
AU2002231654A1 (en) 2000-12-07 2002-06-18 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Pharmaceutical paste comprising an acid-labile active ingredient
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
JP2002234842A (en) * 2001-02-09 2002-08-23 Kyowa Yakuhin Kogyo Kk Oral enteric pharmaceutical preparation
CA2440588C (en) * 2001-03-13 2010-02-09 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
US7309783B2 (en) * 2001-05-09 2007-12-18 The University Of Connecticut Mammalian early developmental regulator gene
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US6543389B2 (en) 2001-06-26 2003-04-08 Pfizer Inc. Insecticidal pet collar
US8309118B2 (en) 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
JP2005509605A (en) * 2001-09-28 2005-04-14 マクニール−ピーピーシー・インコーポレイテッド A dosage form comprising an edible composition and an edible skin
CA2463690C (en) * 2001-10-17 2011-08-23 Takeda Chemical Industries, Ltd. Granules containing acid-unstable chemical in large amount
ES2198195B1 (en) 2001-12-18 2004-10-01 Laboratorios Del Dr. Esteve, S.A. COMPRESSED ORAL PHARMACEUTICAL DOSAGE FORM, WITH ENTERIC COATING, CONTAINING A LABIL BENCIMIDAZOL COMPOUND IN THE MIDDLE ACID.
US20040006111A1 (en) * 2002-01-25 2004-01-08 Kenneth Widder Transmucosal delivery of proton pump inhibitors
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US7429619B2 (en) 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
WO2004016242A2 (en) * 2002-08-16 2004-02-26 Themis Laboratories Private Limited A process for manufacture of stable oral multiple units pharamceutical composition containing benzimidazoles
US20050191353A1 (en) * 2002-08-16 2005-09-01 Amit Krishna Antarkar Process for manufacture of stable oral multiple unit pharmaceutical composition containing benzimidazoles
US7135324B2 (en) * 2002-09-04 2006-11-14 The University Of Connecticut Viral recombinases, related articles, and methods of use thereof
JP4169329B2 (en) * 2002-10-04 2008-10-22 村樫石灰工業株式会社 Slaked lime-based coating composition
ES2534713T3 (en) 2002-10-16 2015-04-27 Takeda Pharmaceutical Company Limited Stable solid preparations
CA2503150A1 (en) * 2002-10-31 2004-05-21 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
US6893660B2 (en) * 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
WO2004066924A2 (en) * 2003-01-24 2004-08-12 Andrx Labs Llc Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
US20040146558A1 (en) * 2003-01-28 2004-07-29 Kyowa Pharmaceutical Co., Ltd. Oral enteric-coated preparation
JP2006516574A (en) 2003-02-05 2006-07-06 テバ ファーマシューティカル インダストリーズ リミティド Lansoprazole stabilization method
US20040248942A1 (en) * 2003-02-20 2004-12-09 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
EP1617842A1 (en) * 2003-04-22 2006-01-25 Dr. Reddy's Laboratories Ltd. Oral pharmaceutical formulations comprising acid-labile active ingredients and a water-soluble sugar derivate, use thereof and the suitable process for manufacturing these
ES2234393B2 (en) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "FORMULATIONS OF PELETS OF ANTIULCEROSE BENCIMIDAZOLIC COMPOUNDS AND LABILS TO THE ACID".
CL2004000983A1 (en) * 2003-05-08 2005-03-04 Altana Pharma Ag ORAL PHARMACEUTICAL COMPOSITION IN THE FORM OF A TABLET THAT INCLUDES DIHYDRATED MAGNETIC PANTOPRAZOL, WHERE THE TABLET FORM IS COMPOSED BY A NUCLEUS, A MIDDLE COAT AND AN OUTER LAYER; AND USE OF PHARMACEUTICAL COMPOSITION IN ULCERAS AND
PE20050150A1 (en) 2003-05-08 2005-03-22 Altana Pharma Ag A DOSAGE FORM CONTAINING (S) -PANTOPRAZOLE AS AN ACTIVE INGREDIENT
EP2112920B1 (en) * 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
DE10341414A1 (en) * 2003-09-05 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Oral dosage form for poorly soluble acidic and amphoteric agents
US20050053669A1 (en) * 2003-09-05 2005-03-10 Boehringer Ingelheim International Gmbh Administration form for the oral application of poorly soluble acidic and amphorteric drugs
WO2005027878A1 (en) * 2003-09-19 2005-03-31 Penwest Pharmaceuticals Co. Delayed released dosage forms
US20050118267A1 (en) * 2003-09-19 2005-06-02 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
WO2005046634A2 (en) * 2003-11-14 2005-05-26 Siegfried Generics International Ag Gastric juice-resistant form of administration
HU227317B1 (en) * 2003-11-25 2011-03-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Enteric coated tablet containing pantoprazole
CN1321642C (en) * 2003-12-12 2007-06-20 南京长澳医药科技有限公司 Enteric-coated pantoprazole sodium minipill
US20070141150A1 (en) * 2003-12-30 2007-06-21 Raghupathi Kandarapu Pharmaceutical composition
EP1720527A2 (en) * 2004-03-03 2006-11-15 Teva Pharmaceutical Industries Ltd A stable pharmaceutical composition comprising an acid labile drug
CN104292321A (en) 2004-03-29 2015-01-21 株式会社嘉尔药物 Novel modified galectin 9 protein and use thereof
US7491263B2 (en) 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
SI1746980T1 (en) 2004-05-07 2012-03-30 Nycomed Gmbh Pharmaceutical dosage form comprising pellets as well as its manufacturing process
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2006009602A2 (en) 2004-06-16 2006-01-26 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US8658216B2 (en) 2004-12-23 2014-02-25 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
AU2006213439A1 (en) * 2005-01-03 2006-08-17 Lupin Limited Pharmaceutical composition of acid labile substances
US20060165797A1 (en) * 2005-01-12 2006-07-27 Pozen Inc. Dosage form for treating gastrointestinal disorders
EP1845982A2 (en) * 2005-02-02 2007-10-24 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions prepared by non-aqueous layering process
KR100570446B1 (en) * 2005-02-14 2006-04-12 지엘팜텍 주식회사 The enteric coated pharmaceutical oral formulations comprising acid-labile active substances, and a method thereof
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
US20070015782A1 (en) 2005-04-15 2007-01-18 Eisai Co., Ltd. Benzimidazole compound
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
WO2006111853A2 (en) * 2005-04-18 2006-10-26 Aurobindo Pharma Limited Stable solid dosage forms of acid labile drug
US9040564B2 (en) 2005-04-28 2015-05-26 Eisai R&D Management Co., Ltd. Stabilized composition
AU2006242067B2 (en) * 2005-04-28 2012-03-29 Eisai R & D Management Co., Ltd. Stabilized composition
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) * 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US20070026071A1 (en) * 2005-07-28 2007-02-01 Qpharma, Llc Magnesium salt proton pump inhibitor dosage forms
EP1747776A1 (en) * 2005-07-29 2007-01-31 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising granular pantoprazole
KR100591142B1 (en) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 A enteric sustained-release tablet comprising paroxetine
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
EP1967211A4 (en) 2005-12-28 2009-12-30 Takeda Pharmaceutical Method of producing solid preparation disintegrating in the oral cavity
EP1973532A1 (en) * 2006-01-16 2008-10-01 Jubilant Organosys Limited Stable pharmaceutical formulation of an acid labile compound and process for preparing the same
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
CN101453993A (en) 2006-04-03 2009-06-10 伊萨·奥迪迪 Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
AU2007266574A1 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
EP1872778A1 (en) * 2006-06-29 2008-01-02 LEK Pharmaceuticals D.D. Stable pharmaceutical composition with rabeprazole sodium
DK2046334T3 (en) * 2006-07-25 2014-08-25 Vecta Ltd Compositions and Methods to Inhibit Stomach Acid Secretion Using Derivatives of Small Dicarboxylic Acids in Combination with PPI
GB2444593B (en) 2006-10-05 2010-06-09 Santarus Inc Novel formulations for immediate release of proton pump inhibitors and methods of using these formulations
US20080103169A1 (en) 2006-10-27 2008-05-01 The Curators Of The University Of Missouri Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
US8352042B2 (en) * 2006-11-28 2013-01-08 The Alfred E. Mann Foundation For Scientific Research Remote controls and ambulatory medical systems including the same
US20110174855A1 (en) * 2006-11-29 2011-07-21 Yakima Products, Inc. Vehicle top carriers
CN101190208B (en) * 2006-11-30 2011-11-02 石药集团中奇制药技术（石家庄）有限公司 Medicinal preparations containing duloxetine hydrochloride and preparation method thereof
TR201910825T4 (en) 2006-12-22 2019-08-21 Ironwood Pharmaceuticals Inc METHODS AND COMPOSITIONS TO TREAT MEAL PIPE DISEASES
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
CN104069088A (en) 2007-10-12 2014-10-01 武田制药北美公司 Methods of treating gastrointestinal disorders independent of the intake of food
CN101980700A (en) 2008-02-20 2011-02-23 密苏里大学董事会 Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
TWI519322B (en) * 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 Compositions comprising weakly basic drugs and controlled-release dosage forms
US20090263475A1 (en) * 2008-04-21 2009-10-22 Nagaraju Manne Dexlansoprazole compositions
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
WO2009137648A1 (en) * 2008-05-09 2009-11-12 Aptapharma, Inc. Multilayer proton pump inhibitor tablets
KR20110079641A (en) 2008-09-09 2011-07-07 아스트라제네카 아베 Method for delivering a pharmaceutical composition to patient in need thereof
CA2753444A1 (en) * 2009-02-23 2010-08-26 Gopi Venkatesh Controlled-release compositions comprising a proton pump inhibitor
CN101822671A (en) * 2009-03-06 2010-09-08 信谊药厂 Rabeprazde composition and preparation method thereof
SG176724A1 (en) 2009-06-25 2012-01-30 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
US20110008432A1 (en) * 2009-06-25 2011-01-13 Pozen Inc. Method for Treating a Patient in Need of Aspirin Therapy
CN101991543A (en) * 2009-08-10 2011-03-30 杭州赛利药物研究所有限公司 Omeprazole enteric dried suspension agent and preparation method thereof
JP2011037787A (en) * 2009-08-13 2011-02-24 Kyorin Pharmaceutical Co Ltd STABLE RELEASE COMPOSITION INDEPENDENT OF pH OF BASIC DRUG
EP2319504A1 (en) 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical solid dosage form
US20110189271A1 (en) * 2010-02-02 2011-08-04 Vishal Lad Pharmaceutical formulations of acid-labile drugs
US20130202688A1 (en) 2010-05-04 2013-08-08 Sunilendu Bhushan Roy Delayed release oral disintegrating pharmaceutical compositions of lansoprazole
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US20140328861A1 (en) 2011-12-16 2014-11-06 Atopix Therapeutics Limited Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis
CA2860231A1 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
AU2013235422B2 (en) 2012-03-19 2016-12-15 Buck Institute For Research On Aging APP specific BACE inhibitors (ASBIs) and uses thereof
WO2013141827A1 (en) 2012-03-21 2013-09-26 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Enteric coated solid pharmaceutical compositions for proton pump inhibitors
AU2013299656C1 (en) 2012-08-07 2017-06-22 Buck Institute For Research On Aging Multi-component formulation for improving neurological function
US9623047B2 (en) 2012-12-27 2017-04-18 Photo Finish Supplements, Llc Composition and method for improving gastrointestinal health of equine
AU2014207680B2 (en) 2013-01-15 2018-09-06 Ironwood Pharmaceuticals, Inc. Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant
JP6471100B2 (en) 2013-02-12 2019-02-13 バック・インスティテュート・フォー・リサーチ・オン・エイジング Hydantoins that regulate BACE-mediated APP processing
MX2016008689A (en) 2013-12-30 2016-09-06 Avery Dennison Corp Films for printing.
EP2929885A1 (en) 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
EP2933002A1 (en) 2014-04-11 2015-10-21 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of dabigatran and proton pump inhibitors
CA2936740C (en) 2014-10-31 2017-10-10 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
WO2016126625A1 (en) 2015-02-03 2016-08-11 Ironwood Pharmaceuticals, Inc. Methods of treating upper gastrointestinal disorders in ppi refractory gerd
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CN108601746A (en) 2016-01-08 2018-09-28 加利福尼亚大学董事会 The mesoporous silica nano particle with double-layer of lipoid coating for load delivering
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
CN109563089B (en) 2016-05-12 2023-06-16 巴克老年研究所 Compounds that promote normal processing of APP
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP6981088B2 (en) * 2017-01-27 2021-12-15 ニプロ株式会社 Oral solid preparation
CA3067162A1 (en) 2017-06-12 2018-12-20 Glytech Llc. Treatment of depression with nmda antagonists and d2/5ht2a or selective 5ht2a antagonists
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CA3127448A1 (en) 2019-01-22 2020-07-30 Aeovian Pharmaceuticals, Inc. Mtorc modulators and uses thereof
CN114569579B (en) 2020-12-02 2023-10-31 丽珠医药集团股份有限公司 Enteric coated pellets, process for their preparation and formulations containing them
CN112516100A (en) * 2020-12-31 2021-03-19 珠海润都制药股份有限公司 Espressol omeprazole magnesium enteric-coated tablet and preparation method thereof
ES2924573A1 (en) * 2021-03-18 2022-10-07 Aora Health S L MULTI-SITE ADMINISTRATION SYSTEM FOR DIFFERENTIAL ADMINISTRATION IN THE GASTROINTESTINAL TRACT (Machine-translation by Google Translate, not legally binding)
CN115715808A (en) 2021-08-26 2023-02-28 丽珠医药集团股份有限公司 Dry suspension particles for dry suspension agent and preparation method and application thereof
WO2023166488A1 (en) 2022-03-04 2023-09-07 Revagenix, Inc. Broad spectrum aminoglycosides and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2540979A (en) * 1948-04-24 1951-02-06 Smith Kline French Lab Enteric coating
GB760403A (en) * 1952-10-16 1956-10-31 Abbott Lab Improvements in or relating to enteric coatings
GB862376A (en) * 1957-10-10 1961-03-08 Pfizer & Co C Sustained release pharmaceutical tablet
US3131123A (en) * 1959-03-13 1964-04-28 Lab Francais De Therapeutique Enteric tablets and manufacture thereof
GB1190387A (en) * 1966-05-24 1970-05-06 Green Cross Corp Enteric Coated Medicaments
ZA743391B (en) * 1974-05-28 1975-08-27 A Warren Therapeutic products
JPS5157813A (en) * 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
SE7804231L (en) * 1978-04-14 1979-10-15 Haessle Ab Gastric acid secretion
JPS5867616A (en) * 1981-10-15 1983-04-22 Tanabe Seiyaku Co Ltd Enteric microcapsule and its preparation
US4472409A (en) * 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
JPS5920219A (en) * 1982-07-26 1984-02-01 Shin Etsu Chem Co Ltd Preparation of enteric coated pharmaceutical
DE3233764A1 (en) * 1982-09-11 1984-03-15 R.P. Scherer GmbH, 6930 Eberbach Process for the production of oral dosage units
SE8301182D0 (en) * 1983-03-04 1983-03-04 Haessle Ab NOVEL COMPOUNDS
JPS6019715A (en) * 1983-07-12 1985-01-31 Nisshin Flour Milling Co Ltd Stable isocarbostyril pharmaceutical preparation
AU571312B2 (en) * 1984-02-10 1988-04-14 Nycomed Danmark A/S Diffusion coated multiple-units dosage form
SE8404065D0 (en) * 1984-08-10 1984-08-10 Haessle Ab NOVEL BIOLOGICALLY ACTIVE COMPOUNDS
US4685918A (en) * 1985-02-01 1987-08-11 Merck & Co., Inc. Lipid osmotic pump
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
JPS62277322A (en) * 1986-02-13 1987-12-02 Takeda Chem Ind Ltd Stabilized pharmaceutical composition and production thereof
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077541A (en) * 1997-11-14 2000-06-20 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6780435B2 (en) 1997-11-14 2004-08-24 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6855336B2 (en) 1998-08-28 2005-02-15 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation

Also Published As

Publication number Publication date
CS307387A2 (en) 1989-06-13
EP0565210A2 (en) 1993-10-13
HU198385B (en) 1989-10-30
PH24440A (en) 1990-06-25
CN1025151C (en) 1994-06-29
DK169987B1 (en) 1995-04-24
IE61837B1 (en) 1994-11-30
CN87103285A (en) 1987-11-18
DK215987A (en) 1987-10-31
YU46421B (en) 1993-10-20
DE3783386T2 (en) 1993-05-06
AR243377A1 (en) 1993-08-31
ES2010648A4 (en) 1989-12-01
ES2089277T3 (en) 1996-10-01
KR870009718A (en) 1987-11-30
NO174952C (en) 1994-08-10
IE871106L (en) 1987-10-30
EP0244380A3 (en) 1988-10-19
EP0244380A2 (en) 1987-11-04
US4853230A (en) 1989-08-01
NO871791L (en) 1987-11-02
PL265417A1 (en) 1988-07-21
JPS62258316A (en) 1987-11-10
FI91708B (en) 1994-04-29
EP0502556A1 (en) 1992-09-09
HUT44171A (en) 1988-02-29
FI871914A (en) 1987-10-31
ES2010648T3 (en) 1994-07-16
DE3751851T2 (en) 1996-10-31
EP0565210A3 (en) 1995-06-07
GR3007448T3 (en) 1993-07-30
IS1918B (en) 2004-03-15
CS268535B2 (en) 1990-03-14
DD260222B5 (en) 1998-07-09
HK55497A (en) 1997-05-09
FI871914A0 (en) 1987-04-29
DK215987D0 (en) 1987-04-28
NO871791D0 (en) 1987-04-29
HK104095A (en) 1995-07-07
PT84786B (en) 1989-12-29
DZ1078A1 (en) 2004-09-13
ZA872379B (en) 1987-12-30
YU68087A (en) 1988-08-31
CY1860A (en) 1987-04-16
EG18517A (en) 1993-04-30
PT84786A (en) 1987-05-01
EP0244380B1 (en) 1993-01-07
DE244380T1 (en) 1990-02-08
JPH0667837B2 (en) 1994-08-31
DE3751851D1 (en) 1996-08-01
GB2189699A (en) 1987-11-04
ATE139692T1 (en) 1996-07-15
AU603568B2 (en) 1990-11-22
ATE186639T1 (en) 1999-12-15
EP0502556B1 (en) 1996-06-26
NO174952B (en) 1994-05-02
AU7192287A (en) 1987-11-05
MY102675A (en) 1992-09-30
DE3783386D1 (en) 1993-02-18
IS3222A7 (en) 1987-10-31
EP0565210B1 (en) 1999-11-17
SU1709894A3 (en) 1992-01-30
KR950004886B1 (en) 1995-05-15
NZ220097A (en) 1990-04-26
GB8610573D0 (en) 1986-06-04
FI91708C (en) 1994-08-10
GR890300156T1 (en) 1990-03-14

Similar Documents

Publication Publication Date Title
CA1302891C (en) Pharmaceutical formulations of acid labile substances for oral use
EP0496437B1 (en) Use of specific core material and layers to obtain pharmaceutical formulations stable to discolouration of omeprazole
CA2290531C (en) Pharmaceutical formulation of omeprazole
AU774278B2 (en) Pharmaceutical formulation comprising omeprazole
IL121652A (en) Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a prokinetic agent
EP0768872A1 (en) New oral pharmaceutical formulation containing magnesium salt of omeprazole
HRP920855A2 (en) Pharmaceutical formulations of acid labile substances for oral use
AU695723C (en) New oral pharmaceutical formulation containing magnesium salt of omeprazole
DD260222A5 (en) A process for preparing an oral pharmaceutical preparation containing an acid labile compound

Legal Events

Date Code Title Description
MKEX Expiry